Ebenbuild

Our CEO, Kei Wieland Müller, has been selected to present at LSI USA '25 in Dana Point on Tuesday, March 18! Kei will be sharing insights into Ebenbuild’s lung digital twin platform technology and its cutting-edge application to personalizing mechanical ventilation for critically ill patients. By leveraging patient-specific data, Ebenbuild will enable more effective treatment, helping clinicians make efficient, better-informed decisions when it matters most. We seek to shape the future of precision medicine for respiratory care, and are thrilled to be part of the conversation at LSI. If you’re attending, be sure to catch Kei’s talk and connect with us! #LSIUSA #DigitalTwins #AIinHealthcare

We are thrilled to announce that Ebenbuild has been accepted into the Life Sciences U.S. market access program of the German Accelerator, supported by the Federal Ministry for Economic Affairs and Climate Action! The program will boost our efforts to bring our innovative digital lung twin technology to the U.S. market. Over the next few months, we will work closely with a network of seasoned U.S. experts with whom we'll fine-tune our regulatory and go-to-market strategy to navigate the complexities of entering the U.S. healthcare system. We look forward to impactful sessions that will help shape how we improve outcomes for patients suffering from acute lung complications such as ARDS.

🌟 Wrapping Up an Inspiring DDL 2024! 🌟 Last week, we had the privilege of being part of DDL 2024, a hub of innovation, collaboration, and forward-thinking ideas in the respiratory field. It wasn’t just about showcasing our work—it was about diving into real conversations, exploring new ideas, and feeling the buzz of this amazing community. For us, learning never stops. Whether chatting over coffee or diving into deep discussions, DDL left us with fresh ideas we can’t wait to put into action. 🚀 To all the brilliant minds we connected with: thank you for the passion and curiosity you brought to the table. Let’s keep this momentum going as we head into 2025! #DDL2024 #Collaboration #Innovation #AlwaysLearning

"Tages Arbeit, abends Gäste! Saure Wochen, frohe Feste!" In our own words: Challenges overcome, collaborations expanded, customers won...time for some pizza 🍕 Our Christmas party was a blast! When high energy levels at work carry over after hours, you know it's an exceptional team 😉 : A team spearheading personalized AI/physics-based lung digital twin technology, inspiring excitement among key opinion leaders worldwide, and lots of fun to hang out with. We'll wind down over Christmas to return rested and focused on our goal: precision health intelligence for better patient outcomes in lung diseases. Merry Christmas to everyone!

Gates at #DDL2024 are open, and our team members, Nicolas Schwenck, Jakob Richter, and Maximilian Grill are waiting for you at booth #198. Make sure to stop by and learn about the possibilities and potential of #insilicotrials.

🌬️ Meet Ebenbuild at DDL 2024! 🌬️ We’re excited to announce our participation in the DDL Conference this year! Join us at Booth # 198 to discover how our software provides #insilicotrials for respiratory drug delivery, and is transforming respiratory drug development. 🚀 Let’s talk about how we can accelerate your R&D projects. 🔗 Schedule a meeting with us in advance to secure your spot for a deeper discussion during the event. Let’s make this DDL conference a platform for innovation and collaboration! See you there! #DDL2024 #RespiratoryDrugDelivery #Ebenbuild #InSilicoTrials #Innovation Dr.-Ing. Nicolas Schwenck Maximilian Grill Jakob Richter

Charles Taylor appointed Chairman of the Board. Today, we are delighted to announce that industry veteran and renowned researcher Dr. Charles Taylor has been appointed Chairman of the Board. Charles is a founder of HeartFlow and a pioneer in the field of predictive, simulation-based medicine. His unparalleled expertise and excellent industry network of key opinion leaders, investors, and healthcare companies will be invaluable as we work together to bring our products to the US healthcare system. Read the full press release here: https://lnkd.in/dxeRJUw8

Spent two inspiring days at the German Aerosol Therapy Symposium (#DATS) last week. I particularly enjoyed the interdisciplinary program and discussions with experts from the various fields that are essential for the advancement of inhalation therapies. Many thanks to the organizers for inviting me to present on “Patient-specific computer models of the human lung to predict aerosol deposition.” It was a privilege to contribute to an event with over 30 years of history, originally initiated by Gerhard Scheuch, and to be part of such a well-curated program. Karin Caspar, Sabine Häussermann, Philipp Kroneberg, Otmar Schmid, Katharina Schwarz

Had a great experience attending and presenting at the MVIC Symposium this week. Many thanks to the organizers (Lars Asking, Hanna Nicklasson, Mats Håkansson, MVIC AB) for such a well-organized event that encouraged fruitful discussions and new connections. It was also great to catch up with familiar faces. Looking forward to coming back next year! #mvicsymposium #mvic #insilicotrials #inhaleddrugs #drugdevelopment

Meet us in Lund this week, where our Head of In Silico Trials Maximilian Grill will talk about “Optimizing inhaled drug development through in silico trials”. Find out more here: https://lnkd.in/edxe9scz #mvicsymposium #mvic #insilicotrials #inhaleddrugs #drugdevelopment